| __timestamp | Blueprint Medicines Corporation | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 9689000 |
| Thursday, January 1, 2015 | 14456000 | 10431000 |
| Friday, January 1, 2016 | 19218000 | 9618000 |
| Sunday, January 1, 2017 | 27986000 | 12348000 |
| Monday, January 1, 2018 | 47928000 | 28310241 |
| Tuesday, January 1, 2019 | 96388000 | 59336147 |
| Wednesday, January 1, 2020 | 157743000 | 159145941 |
| Friday, January 1, 2021 | 195293000 | 199800000 |
| Saturday, January 1, 2022 | 237374000 | 90225000 |
| Sunday, January 1, 2023 | 295141000 | 92538000 |
| Monday, January 1, 2024 | 359272000 |
Cracking the code
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Blueprint Medicines Corporation and MorphoSys AG have demonstrated contrasting approaches to SG&A expenditures. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, peaking at nearly $295 million in 2023. This aggressive spending reflects their commitment to expanding market reach and operational capabilities. In contrast, MorphoSys AG's SG&A expenses grew by approximately 850% during the same period, reaching around $92 million in 2023. This more conservative approach suggests a focus on sustainable growth and cost management. As these companies continue to evolve, their SG&A strategies will likely play a pivotal role in shaping their competitive landscapes.
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
MorphoSys AG and Evotec SE: SG&A Spending Patterns Compared